Global Male Fertility Market - Industry Scenario, Market Size, Outlook, Trend and Forecast, 2019 to 2027

Male Fertility Market globally would reach by revenue to a market size of USD 5.14 billion by 2027 from USD 3.59 in 2020; growing at a compound annual growth rate (CAGR) of 5.1% from 2020 to 2027. The growth of this market is primarily associated with busy and unhealthy lifestyle, obesity, stress, alcohol intake, smoking, globally and adoption of assisted reproductive technologies (ART). These factors are the major market trends driving the market growth and is expected to propel the growth of the male fertility market during the forecast period, i.e., from 2020 to 2027. ART is associated with several solutions for males facing problems related to abnormal sperm quality, low sperm count, and poor motility. In addition, the success rate associated with ART and the ongoing technological advancement are the other driving factors which further boosts the growth of the market.

Companies across the globe are working hard on the recent trends and problems related to male infertility. Continuous research and development (R&D) is on the pace and the key players are heavily investing on the product development to develop devices that would eradicate the root cause of infertility in male. Moreover, commercialization of hormonal therapy is further expected to enhance the growth of the global male fertility market. Reimbursement for infertility related treatments would also fuel the growth of the market in the coming years.

Global male infertility market is segmented by test, treatment and geography. The test segment is further sub-segmented into DNA Fragmentation Technique, Oxidative Stress Analysis, Microscopic Examination, Sperm Agglutination, Computer Assisted Semen Analysis, Sperm Penetration Assay and Others. Treatment segment is sub-segmented into Assisted Reproductive Technology and Varicocele Surgery and Medication. Geography covers all the major four regional market of the world namely North America, Europe, Asia Pacific (APAC) and rest of the World (RoW). Again, these four geographies have been further bi-furcated into their respective countries. For instance, North America includes the U.S., Mexico and Canada. Similarly, European region covered in the scope of the study are the UK, Italy, France, Russia, Germany, and Spain among others; whereas the major countries covered under APAC are Japan, India, and China. Other than North America, Europe and Asia Pacific, the remaining part of the world, i.e., RoW covers Central & South America, Middle East and Africa.

Among test types, DNA fragmentation segments is the leading segment at present holding the major market share as it provides a reliable analysis of sperm DNA integrity. This technique is gaining popularity as DNA fragmentation is the leading cause of infertility in males. Among treatment types, ART is gaining popularity as it helps in treating the problems associated with male fertility such as epididymal dysfunction, sperm autoantibodies, viral orchitis, heat, trauma, accessory gland infection, chemotherapy, and other idiopathic factors. Among the different regions, Europe holds the substantial market share at present due to high adoption of expensive treatment, better scope for diagnosis and treatment, and high awareness level. However, Asia Pacific is would emerge as one of the leading players during the forecast period due to the rising awareness about male infertility diagnostic and treatment. China, India and Singapore are the major countries across Asia Pacific that would add to the growth of the market during the forecast period.

Some of the prominent players in the male infertility market are Aytu BioScience, Inc.; Cadila Healthcare Ltd.; Halotech DNA SL; Bayer Healthcare; Andrology solutions; SCSA diagnostics, Inc.; EMD Sereno, Inc.; and Intas pharmaceuticals Ltd among others. Product development and acquisitions & mergers are some of the key strategies adopted by the key companies of the market.

Market Scope of the Study – Global Male Infertility Market

By Test Segments (Revenue, USD Billion, 2019 - 2027)

• DNA Fragmentation Technique
• Oxidative Stress Analysis
• Microscopic Examination
• Sperm Agglutination
• Computer Assisted Semen Analysis
• Sperm Penetration Assay
• Others

By Treatment Segments (Revenue, USD Billion, 2019 - 2027)

• Assisted Reproductive Technology and Varicocele Surgery
• Medication

By Region Segments (Revenue, USD Billion, 2019 - 2027)

• North America
  • o  U.S.
  • o  Canada
  • o  Mexico
  • Europe
    • o  U.K.
    • o  Germany
    • o  Italy
    • o  France
    • o  Russia
    • o  Spain
    • o  Rest of Europe
    • Asia Pacific (APAC)
      • o  Japan
      • o  China
      • o  India
      • o  Rest of APAC
      • Rest of the World (RoW)
        • o  South and Central America
        • o  Middle East
        • o  Africa